SynthesisFrontiers in immunology2025

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies.

Xiaoshuang Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.